플러스100%마이너스

통합검색
닫기

KMCRIC 챗봇에게

질문하기!

한의약융합데이터센터


근거중심한의약 DB

Home > 한의약융합데이터센터 > 근거중심한의약 DB
Title

Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis.

Authors

Zhang YY, Xia RY, Liang SB, Hu XY, Dai MY, Li YL, Zhao LY, Moore M, Fei YT, Liu JP.

Journal

Integr Med Res.

Year

2021

Vol (Issue)

10(3)

Page

100726.

doi

10.1016/j.imr.2021.100726.

PMID

33996460

Url

http://www.ncbi.nlm.nih.gov/pubmed/33996460

MeSH

Keywords

Chinese herbal medicine; Randomized controlled trials; Respiratory tract infections; Shufeng Jiedu; Systematic review.

한글 키워드

중약; 무작위배정 비교임상연구; 호흡기 감염; 소풍해독교낭; 체계적 문헌고찰.

KMCRIC
Summary & Commentary

KMCRIC 비평 보기 +

Korean Study

Abstract

Background: Shufeng Jiedu capsule has been widely used in China for acute upper respiratory tract infections (AURTIs). The aim of this study was to evaluate its effectiveness and safety for AURTIs.

Methods: Randomized controlled trials comparing SFJD with conventional drug for patients with AURTIs were included. Eight databases were searched from their inceptions to February 2021. Data was synthesized using risk ration (RR) or mean difference (MD) with their 95% confidence interval (CI). The primary outcome was resolution time of typical symptoms.

Results: Twenty-five RCTs involving 3410 patients were included. SFJD in combination with conventional drug was associated with; in common cold shortening the duration of fever (MD -1.54 days, 95% CI [-2.15,-0.92], I 2 = 80%, n = 385, 3 trials) and cough (MD -1.22 days, 95% CI [-1.52, -0.93]); in herpangina, shortening the duration of fever (MD -0.68 days, 95% CI [-1.15, -0.21], I2 = 68%, n = 140, 2 trials) and blistering (MD -0.99 days, 95% CI [-1.23, -0.76], n = 386, 3 trials); in acute tonsillitis and acute pharyngitis shortening the duration of fever (MD -1.13 days, 95% CI [-1.36, -0.90], I 2 = 33%, n = 688, 7 trials) and sore throat (MD -1.13 days, 95% CI [-1.40, -0.86], I 2 = 84.1%, n = 1194, 10 trials). SFJD also improving their cure rate with a range (1-5 days). No serious adverse events were reported.

Conclusion: Low certainty evidence suggests that SFJD appears to shorten the duration of symptoms in AURTIs, improve cure rate and seems safe for application. However, high quality placebo controlled trials are warranted to confirm its benefit.

국문초록

Language

영어

첨부파일